In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

References

• Livio S, Strockbine NA, Panchalingam S, et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis. 2014;59(7):933–941. doi:10.1093/cid/ciu46824958238
   PubMed Web of Science ®Google Scholar
• Zhang W, Luo Y, Li J, et al. Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother. 2011;66(11):2527–2535. doi:10.1093/jac/dkr34121859815
   PubMed Web of Science ®Google Scholar
• Yang H, Chen G, Zhu Y, et al. Surveillance of antimicrobial susceptibility patterns among Shigella species isolated in China during the 7-year period of 2005–2011. Ann Lab Med. 2013;33(2):111–115. doi:10.3343/alm.2013.33.2.11123482897
   PubMed Web of Science ®Google Scholar
• Troeger C, Forouzanfar M, Rao PC, et al.Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(9):909–948. doi:10.1016/S1473-3099(17)30276-128579426
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240–243. doi:10.1016/j.ijantimicag.2009.10.01920034765
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50. doi:10.1016/S1473-3099(09)70325-120129148
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012;31(5):695–701. doi:10.1007/s10096-011-1360-521805292
   PubMed Web of Science ®Google Scholar
• Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122–123.5809587
   PubMed Web of Science ®Google Scholar
• Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364–386.4605290
   PubMed Web of Science ®Google Scholar
• Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34(6):853–858.7730229
   PubMed Web of Science ®Google Scholar
• Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29(2):127–142. doi:10.1007/s10096-009-0833-219915879
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008;27(6):439–443. doi:10.1007/s10096-007-0456-418214558
   PubMed Web of Science ®Google Scholar
• Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82–83. doi:10.1016/j.ijantimicag.2010.09.00221074377
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255–268. doi:10.1093/jac/dkr46622096042
   PubMed Web of Science ®Google Scholar
• Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2015;70(11):3042–3050. doi:10.1093/jac/dkv22126209311
   PubMed Web of Science ®Google Scholar
• Pogue JM, Marchaim D, Kaye D, Kaye KS. Revisiting “older” antimicrobials in the era of multidrug resistance. Pharmacotherapy. 2011;31(9):912–921. doi:10.1592/phco.31.9.91221923592
   PubMed Web of Science ®Google Scholar
• Walsh CC, Landersdorfer CB, McIntosh MP, et al. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother. 2016;71(8):2218–2229. doi:10.1093/jac/dkw11527118778
   PubMed Web of Science ®Google Scholar
• Yamada S, Hyo Y, Ohmori S, Ohuchi M. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy. 2007;53(3):202–209. doi:10.1159/00010081117356268
   PubMed Web of Science ®Google Scholar
• Hornsey M, Phee L, Longshaw C, Wareham DW. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2013;41(3):285–287. doi:10.1016/j.ijantimicag.2012.11.01323312607
   PubMed Web of Science ®Google Scholar
• Yang H, Chen G, Hu L, et al. In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2015;45(2):188–191. doi:10.1016/j.ijantimicag.2014.10.01225440154
   PubMed Web of Science ®Google Scholar
• Yang H, Chen G, Hu L, et al. Enhanced efficacy of imipenem-colistin combination therapy against multiple-drug-resistant Enterobacter cloacae: in vitro activity and a Galleria mellonella model. J Microbiol Immunol Infect. 2018;51(1):70–75. doi:10.1016/j.jmii.2016.01.00326906264
   PubMedGoogle Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg48612805255
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Van Bambeke F, Canton R, et al. Reviving old antibiotics. J Antimicrob Chemother. 2015;70(8):2177–2181. doi:10.1093/jac/dkv15726063727
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–59. doi:10.1016/j.ijantimicag.2013.09.01024183799
   PubMed Web of Science ®Google Scholar
• Traunmuller F, Popovic M, Konz KH, Vavken P, Leithner A, Joukhadar C. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet. 2011;50(8):493–503. doi:10.2165/11592670-000000000-0000021740073
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119(4):1114–1122.11296178
   PubMed Web of Science ®Google Scholar
• Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RJ, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother. 2009;53(6):2605–2609. doi:10.1128/AAC.01533-0819332683
   PubMed Web of Science ®Google Scholar
• Wei WJ, Yang HF, Ye Y, Li JB. Galleria mellonella as a model system to assess the efficacy of antimicrobial agents against Klebsiella pneumoniae infection. J Chemother. 2017;29(4):252–256. doi:10.1080/1120009X.2016.115689227237961
   PubMed Web of Science ®Google Scholar
• Jonsson R, Struve C, Jenssen H, Krogfelt KA. The wax moth Galleria mellonella as a novel model system to study Enteroaggregative Escherichia coli pathogenesis. Virulence. 2017;8(8):1894–1899. doi:10.1080/21505594.2016.125653727824518
   PubMed Web of Science ®Google Scholar
• Thomas RJ, Hamblin KA, Armstrong SJ, et al. Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei. Int J Antimicrob Agents. 2013;41(4):330–336. doi:10.1016/j.ijantimicag.2012.12.00923402703
   PubMed Web of Science ®Google Scholar
• Barnoy S, Gancz H, Zhu Y, Honnold CL, Zurawski DV, Venkatesan MM. The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence. Gut Microbes. 2017;8(4):335–350. doi:10.1080/19490976.2017.129322528277944
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347. doi:10.1128/CMR.00068-1526960938
   PubMed Web of Science ®Google Scholar